Lupin Ranks No. 1 Globally in Pharma in S&P ESG Assessment 2025

Mumbai, February 27, 2026: Lupin Limited has ranked No. 1 globally in the pharmaceutical sector in the S&P Global Corporate Sustainability Assessment (CSA) 2025, with a score of 91 out of 100. The company also topped all sectors in India in the assessment, according to a company statement

The S&P Global Corporate Sustainability Assessment is an ESG benchmark that evaluates companies across economic, environmental and social criteria specific to their industries. More than 9,200 companies across 59 industries were assessed, and 848 were included in the Sustainability Yearbook 2026

Lupin has been included in the Sustainability Yearbook for the third consecutive year. Yearbook members are selected based on their scores in the 2025 CSA and must rank within the top 15% of their industry and within 30% of the industry’s top performer

Ramesh Swaminathan, Executive Director, Global CFO and Head of IT and API Plus SBU, Lupin, said, “This recognition by S&P Global places Lupin among the topmost global sustainability leaders and reinforces our long-term commitment to embedding ESG principles into our business strategy. It strengthens our resolve to accelerate our sustainability roadmap and deepen ESG integration across our value chain, while continuing to create positive outcomes for patients, communities, and stakeholders worldwide.”

The company stated that the recognition reflects its focus on governance, environmental management and social impact across its global operations

Headquartered in Mumbai, Lupin operates in over 100 markets and has 15 manufacturing sites and 7 research centres globally.